Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
about
Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue TargetingAmyloid diseases of the heart: current and future therapiesRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisUtility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosiStanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicityCardiac amyloidosis responding to bortezomib: case report and review of literature.Worming along in amyloid cardiotoxicity.A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosisCardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failureSystemic and microvascular oxidative stress induced by light chain amyloidosis.The evolving use of serum free light chain assays in haematology.A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli.Amyloidosis: pathogenesis and new therapeutic options.Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteinsLight Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human CardiomyocytesHyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and ratsCurrent perspectives on cardiac amyloidosis.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Targeting protein aggregation for the treatment of degenerative diseasesProtective role of clusterin in preserving endothelial function in AL amyloidosisAl amyloidosisThe workings of the amyloid diseases.Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsCardiovascular magnetic resonance and prognosis in cardiac amyloidosisLong term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experiencePerspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodiesHuman amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafishMonosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain ProteinsCurrent trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.Incidence, diagnosis and prognosis of cardiac amyloidosis.Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up studyCardiac amyloidosis: an approach to diagnosis and management.Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Cardiac amyloidosis: the heart of the matter.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Pathophysiology and treatment of systemic amyloidosis.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
P2860
Q26744469-3BC8ACEA-E0E2-4CA5-B90F-5E7D4992ED1FQ27023836-2773ED23-88AB-4DCE-B978-607901EFACC7Q28069975-394CE03F-9727-4B14-9965-52B959DBDC4FQ30469018-CF9EC09B-C5D7-47EB-B1E9-7C72404A1116Q30570936-497BC51B-6FB9-42E8-9CC6-69F0746E4122Q33654026-FD4653FC-D28D-499C-9658-E8BEB6BDE725Q33718793-384215E5-B9C2-48CD-8510-A58DBDF9A797Q33718805-E2B9BC05-2C15-4C06-AA8C-2C689B6B30AEQ34240595-8498D44E-350B-4367-9889-CEF91AE7FD99Q34283343-DB526044-737F-431A-AA0F-9FE67144B110Q34758218-25BAAAFD-001B-409E-B4B4-0B09003CF848Q35006134-43AF3B81-2DF8-47DB-BDF1-339DD6426C4AQ35111771-E1CD8E8E-638E-4FD9-82A3-4C991E982455Q35601377-79253134-4E99-465B-B663-A04FD88478D1Q35783283-7A61356C-D6C8-4A10-AF41-7CFB17110755Q35829973-9193FA09-B923-4479-9626-FB247F5D3386Q35964900-FF7E4B03-56C7-45EB-86A7-A959BF75914FQ36015183-30B51427-8F9B-4BC4-B5B2-FB8004452F61Q36235980-FA6B7FEB-FF92-4B3D-B342-FF9C09203177Q36339136-1CAD87C6-7092-4E40-B576-9B30AE1507FFQ36392233-44A384DC-2D2A-4A06-AB07-E291298FF84BQ36801112-939BBD61-71E6-4D39-A085-5DC8E66FDE8CQ36950813-4D131D81-B6C9-4DB7-A164-089C5B7D56B5Q37020261-9DECC0DC-6886-4C4D-9697-8F9EC0E152DAQ37035201-E05D1676-539A-48E5-A75D-BD6865802188Q37045885-19AAD973-F501-4ACF-BD63-BEE247947FCCQ37045900-9B73499F-37FF-4B0D-9CF3-26AE9B4B00AAQ37050005-DA6FCB22-5BCE-454A-A47C-E5B20738162BQ37054932-2D339481-A779-4766-8EAB-FB96440982F1Q37076162-1581BAAC-12E6-4A16-BAFE-27A0E87D297CQ37370051-92875603-4E7B-412F-97DC-F99706BBCD2BQ37399628-2EAC8C6E-1225-49E2-BB8B-1D8C113A928DQ37673360-0CDB9C54-821C-4B35-9614-712DDA4A0CF2Q37710999-50CB8828-7E49-4666-B183-2AA635F248CFQ37770112-8A1F8504-AEF6-4C0E-846E-4D501E5558DCQ37821496-82E93482-B60F-465A-8BEF-7056FE7238CEQ37899075-8FE431EA-756F-4EB6-957A-A80661853890Q37999957-5016ED8C-2D85-4BD6-98EF-DA00117696FCQ38131710-63F5EE54-226B-4D88-8B64-3C3DA0746C19Q38168869-8CF0FEFE-2328-42C0-81CD-82E249C33573
P2860
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Circulating amyloidogenic free ...... improvement of survival in AL.
@en
Circulating amyloidogenic free ...... improvement of survival in AL.
@nl
type
label
Circulating amyloidogenic free ...... improvement of survival in AL.
@en
Circulating amyloidogenic free ...... improvement of survival in AL.
@nl
prefLabel
Circulating amyloidogenic free ...... improvement of survival in AL.
@en
Circulating amyloidogenic free ...... improvement of survival in AL.
@nl
P2093
P50
P1433
P1476
Circulating amyloidogenic free ...... improvement of survival in AL
@en
P2093
GianVico Melzi D'Eril
Paola Russo
Remigio Moratti
Roberto Fogari
Tiziana Bosoni
Vittorio Perfetti
P304
P356
10.1182/BLOOD-2005-11-4385
P407
P50
P577
2006-01-24T00:00:00Z